Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GMED NYSE:HAE NYSE:HRC NYSE:INSP NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$57.09-1.2%$60.18$54.48▼$94.93$7.72B1.191.15 million shs887,036 shsHAEHaemonetics$75.54-3.4%$70.50$55.30▼$94.99$3.64B0.39673,975 shs431,470 shsHRCHill-Rom$155.96$155.74$93.34▼$156.22$10.30B0.55656,912 shsN/AINSPInspire Medical Systems$130.55-6.2%$139.66$123.00▼$225.00$3.86B1.25555,191 shs374,932 shsTNDMTandem Diabetes Care$15.62-3.4%$20.41$15.17▼$48.24$1.05B1.481.49 million shs834,019 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical+0.86%-2.27%-5.91%-20.61%-16.83%HAEHaemonetics+0.72%+1.96%+8.56%+30.66%-10.00%HRCHill-Rom0.00%0.00%0.00%0.00%0.00%INSPInspire Medical Systems+3.55%+8.48%+1.99%-5.32%+5.89%TNDMTandem Diabetes Care+2.02%-5.24%-27.94%-5.22%-63.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMEDGlobus Medical4.9407 of 5 stars4.35.00.04.12.02.51.9HAEHaemonetics4.6941 of 5 stars3.52.00.04.32.81.72.5HRCHill-RomN/AN/AN/AN/AN/AN/AN/AN/AINSPInspire Medical Systems4.8265 of 5 stars4.41.00.04.82.92.51.9TNDMTandem Diabetes Care4.1754 of 5 stars4.21.00.04.92.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMEDGlobus Medical 2.62Moderate Buy$94.0064.65% UpsideHAEHaemonetics 3.00Buy$97.3028.80% UpsideHRCHill-Rom 0.00N/AN/AN/AINSPInspire Medical Systems 2.73Moderate Buy$211.9162.32% UpsideTNDMTandem Diabetes Care 2.33Hold$32.71109.51% UpsideCurrent Analyst Ratings BreakdownLatest HRC, INSP, HAE, GMED, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025HAEHaemoneticsBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$95.007/9/2025HAEHaemoneticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$90.007/9/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.006/26/2025HAEHaemoneticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/25/2025HAEHaemoneticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.006/10/2025GMEDGlobus MedicalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/27/2025GMEDGlobus MedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/27/2025GMEDGlobus MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/20/2025HAEHaemoneticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMEDGlobus Medical$2.52B3.07$6.63 per share8.61$30.40 per share1.88HAEHaemonetics$1.36B2.67$7.02 per share10.76$16.34 per share4.62HRCHill-Rom$3.02B3.41$9.29 per share16.79$28.56 per share5.46INSPInspire Medical Systems$802.80M4.80$1.66 per share78.69$23.01 per share5.67TNDMTandem Diabetes Care$982.95M1.06N/AN/A$4.01 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMEDGlobus Medical$102.98M$1.3442.5714.171.677.39%10.52%8.56%8/5/2025 (Estimated)HAEHaemonetics$167.68M$3.3122.8614.991.2612.32%26.37%9.22%8/14/2025 (Estimated)HRCHill-Rom$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/AINSPInspire Medical Systems$53.51M$2.1760.2940.542.067.92%10.00%8.68%8/5/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)Latest HRC, INSP, HAE, GMED, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40N/AN/AN/A$238.39 millionN/A8/5/2025Q2 2025GMEDGlobus Medical$0.79N/AN/AN/A$738.91 millionN/A8/5/2025Q2 2025INSPInspire Medical Systems$0.22N/AN/AN/A$214.50 millionN/A5/8/2025Q1 2025GMEDGlobus Medical$0.74$0.68-$0.06$0.54$629.74 million$598.12 million5/8/2025Q4 2025HAEHaemonetics$1.22$1.24+$0.02$1.17$329.38 million$330.60 million5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMEDGlobus MedicalN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/AHRCHill-Rom$0.960.62%N/A25.81%N/AINSPInspire Medical SystemsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMEDGlobus MedicalN/A4.452.72HAEHaemonetics1.121.620.99HRCHill-Rom0.971.381.05INSPInspire Medical SystemsN/A9.017.44TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMEDGlobus Medical95.16%HAEHaemonetics99.67%HRCHill-Rom76.45%INSPInspire Medical Systems94.91%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipGMEDGlobus Medical18.51%HAEHaemonetics1.84%HRCHill-Rom0.69%INSPInspire Medical Systems4.10%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMEDGlobus Medical5,300135.38 million110.32 millionOptionableHAEHaemonetics3,02348.04 million47.16 millionOptionableHRCHill-Rom10,00066.05 million65.59 millionOptionableINSPInspire Medical Systems1,24629.49 million28.29 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableHRC, INSP, HAE, GMED, and TNDM HeadlinesRecent News About These CompaniesCitigroup Reaffirms Sell Rating for Tandem Diabetes Care (NASDAQ:TNDM)July 11 at 2:21 AM | americanbankingnews.comTandem Diabetes stock falls after Citi downgrades to Sell on competition concernsJuly 9 at 6:56 PM | au.investing.comCiti adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem DiabetesJuly 9 at 6:56 PM | finance.yahoo.comTandem Diabetes Shares Drop Following Citi Downgrade Over Rising CompetitionJuly 9 at 6:56 PM | msn.comWhy Tandem Diabetes (TNDM) Shares Are Sliding TodayJuly 9 at 6:56 PM | msn.comTandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month Low - Here's WhyJuly 9 at 12:15 PM | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Given "Sell" Rating at CitigroupJuly 9 at 8:40 AM | marketbeat.comFurther weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83%July 7, 2025 | finance.yahoo.comMirae Asset Global Investments Co. Ltd. Sells 265,554 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 6, 2025 | marketbeat.comTandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - MorningstarJuly 2, 2025 | morningstar.comMRSI Alert: Tandem Diabetes Care (TNDM) Now OversoldJuly 2, 2025 | nasdaq.comTNDM - Tandem Diabetes Care Inc Key Metrics - MorningstarJuly 1, 2025 | morningstar.comMTandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025July 1, 2025 | businesswire.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - Here's WhyJuly 1, 2025 | marketbeat.comTNDM - Tandem Diabetes Care Inc Financials - MorningstarJune 27, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Tandem Diabetes’s Q1 Earnings CallJune 27, 2025 | msn.comTNDM | Tandem Diabetes Care Inc. Annual Cash Flow Statement - MarketWatchJune 26, 2025 | marketwatch.comTandem Diabetes Care (NASDAQ:TNDM) Shares Down 5.9% - Time to Sell?June 25, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Recommendation of "Hold" by BrokeragesJune 25, 2025 | marketbeat.comTandem Diabetes Care Inc TNDM Company Vitals - U.S. NewsJune 24, 2025 | money.usnews.comTNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3June 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense330% Returns YTD: Is CoreWeave's Momentum Softening?By Nathan Reiff | June 18, 2025View 330% Returns YTD: Is CoreWeave's Momentum Softening?HRC, INSP, HAE, GMED, and TNDM Company DescriptionsGlobus Medical NYSE:GMED$57.09 -0.71 (-1.23%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Haemonetics NYSE:HAE$75.54 -2.63 (-3.36%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Hill-Rom NYSE:HRCHill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.Inspire Medical Systems NYSE:INSP$130.55 -8.70 (-6.25%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Tandem Diabetes Care NASDAQ:TNDM$15.62 -0.56 (-3.43%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
